About AstraZeneca PLC
https://www.astrazeneca.comAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
CEO
Pascal Claude Roland Soriot
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Drug Manufacturers - General
Sector Healthcare
Went public May 12, 1993
Method of going public Dual Listing
Full time employees 94,300
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-07-27 | Forward | 2:1 |
| 1998-04-08 | Forward | 3:1 |
ETFs Holding This Stock
Summary
Total 193
Showing Top 3 of 193
Ratings Snapshot
Rating : B+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 4
Debt To Equity 1
Price To Earnings 2
Price To Book 2
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $108
Target Low $97
Target Median $103
Target Consensus $102.67
Institutional Ownership
PRICE T ROWE ASSOCIATES INC /MD/
Shares:49.12M
Value:$4.73B
PRIMECAP MANAGEMENT CO/CA/
Shares:39.86M
Value:$3.84B
BANK OF AMERICA CORP /DE/
Shares:32.63M
Value:$3.14B
Summary
% Of Shares Owned 11.01%
Total Number Of Holders 1,646
Showing Top 3 of 1,646
Market Cap $291.48 B
52w High $96.51
52w Low $61.24
Dividend Yield 2.13%
Frequency Semi-Annual
P/E 32.01
Volume 5.29M
Outstanding Shares 3.10B
About AstraZeneca PLC
https://www.astrazeneca.comAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $15.19B ▲ | $8.75B ▲ | $2.53B ▲ | 16.67% ▼ | $0.82 ▲ | $5.14B ▲ |
| Q2-2025 | $14.46B ▲ | $8.48B ▲ | $2.45B ▼ | 16.95% ▼ | $0.79 ▼ | $4.96B ▼ |
| Q1-2025 | $13.59B ▼ | $7.67B ▼ | $2.92B ▲ | 21.46% ▲ | $0.94 ▲ | $5.04B ▲ |
| Q4-2024 | $14.89B ▲ | $10.13B ▲ | $1.5B ▲ | 10.07% ▼ | $0.49 ▲ | $2.81B ▼ |
| Q3-2024 | $13.56B | $8.38B | $1.43B | 10.53% | $0.46 | $4.1B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $8.18B ▲ | $114.46B ▲ | $68.48B ▲ | $45.89B ▲ |
| Q2-2025 | $7.11B ▲ | $112.42B ▲ | $67.61B ▲ | $44.72B ▲ |
| Q1-2025 | $5.39B ▼ | $106.25B ▲ | $65.12B ▲ | $41.04B ▲ |
| Q4-2024 | $5.65B ▲ | $104.03B ▼ | $63.16B ▼ | $40.79B ▲ |
| Q3-2024 | $4.93B | $104.92B | $64.12B | $40.72B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.53B ▼ | $5.13B ▲ | $-2B ▲ | $-2.07B ▼ | $1.05B ▼ | $4.45B ▲ |
| Q2-2025 | $3.13B ▲ | $3.39B ▼ | $-2.11B ▼ | $518M ▲ | $1.82B ▲ | $1.46B ▼ |
| Q1-2025 | $2.92B ▲ | $3.71B ▲ | $-1.25B ▼ | $-2.71B ▼ | $-222M ▼ | $3.28B ▲ |
| Q4-2024 | $1.67B ▼ | $2.91B ▼ | $-1.18B ▲ | $-671M ▲ | $994M ▲ | $1.95B ▼ |
| Q3-2024 | $1.83B | $3.38B | $-1.51B | $-4.13B | $-2.24B | $2.02B |
Revenue by Products
| Product | Q2-2019 | Q2-2021 | Q2-2022 | Q2-2023 |
|---|---|---|---|---|
 Andexxa | $0 ▲ | $0 ▲ | $20.00M ▲ | $40.00M ▲ |
 Bevespi | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 BioPharmaceuticals total Respiratory Immunology | $0 ▲ | $0 ▲ | $650.00M ▲ | $1.48Bn ▲ |
 Breztri | $0 ▲ | $60.00M ▲ | $50.00M ▼ | $160.00M ▲ |
 Brilinta | $390.00M ▲ | $380.00M ▼ | $180.00M ▼ | $330.00M ▲ |
 Bydureon | $140.00M ▲ | $100.00M ▼ | $60.00M ▼ | $40.00M ▼ |
 Calquence | $60.00M ▲ | $280.00M ▲ | $400.00M ▲ | $650.00M ▲ |
 Crestor | $310.00M ▲ | $270.00M ▼ | $20.00M ▼ | $280.00M ▲ |
 DalirespDaxas | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ | $20.00M ▼ |
 Enhertu | $0 ▲ | $0 ▲ | $20.00M ▲ | $70.00M ▲ |
 Farxiga | $380.00M ▲ | $730.00M ▲ | $280.00M ▼ | $1.50Bn ▲ |
 Fasenra | $170.00M ▲ | $320.00M ▲ | $230.00M ▼ | $410.00M ▲ |
 Faslodex | $270.00M ▲ | $100.00M ▼ | $10.00M ▼ | $80.00M ▲ |
 FluMist | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Imfinzi | $340.00M ▲ | $600.00M ▲ | $370.00M ▼ | $1.08Bn ▲ |
 Kanuma | $0 ▲ | $0 ▲ | $20.00M ▲ | $50.00M ▲ |
 Koselugo | $0 ▲ | $0 ▲ | $50.00M ▲ | $80.00M ▲ |
 Lokelma | $0 ▲ | $40.00M ▲ | $40.00M ▲ | $100.00M ▲ |
 Lynparza | $280.00M ▲ | $590.00M ▲ | $310.00M ▼ | $720.00M ▲ |
 Nexium | $390.00M ▲ | $340.00M ▼ | $30.00M ▼ | $250.00M ▲ |
 Oncology Others | $0 ▲ | $0 ▲ | $0 ▲ | $50.00M ▲ |
 Onglyza | $120.00M ▲ | $100.00M ▼ | $20.00M ▼ | $70.00M ▲ |
 Other Others | $0 ▲ | $0 ▲ | $10.00M ▲ | $50.00M ▲ |
 Pulmicort | $330.00M ▲ | $170.00M ▼ | $10.00M ▼ | $120.00M ▲ |
 Respiratory Others | $0 ▲ | $0 ▲ | $50.00M ▲ | $70.00M ▲ |
 Roxadustat | $0 ▲ | $50.00M ▲ | $50.00M ▲ | $70.00M ▲ |
 Saphnelo | $0 ▲ | $0 ▲ | $20.00M ▲ | $70.00M ▲ |
 SelokenToprolXL | $170.00M ▲ | $270.00M ▲ | $220.00M ▼ | $160.00M ▼ |
 Soliris | $0 ▲ | $0 ▲ | $570.00M ▲ | $810.00M ▲ |
 Strensiq | $0 ▲ | $0 ▲ | $190.00M ▲ | $300.00M ▲ |
 Symbicort | $580.00M ▲ | $680.00M ▲ | $220.00M ▼ | $600.00M ▲ |
 Synagis | $100.00M ▲ | $20.00M ▼ | $0 ▼ | $90.00M ▲ |
 Tagrisso | $780.00M ▲ | $1.31Bn ▲ | $510.00M ▼ | $1.49Bn ▲ |
 Total Oncology | $0 ▲ | $0 ▲ | $1.60Bn ▲ | $4.38Bn ▲ |
 Total Other medicines | $0 ▲ | $0 ▲ | $40.00M ▲ | $300.00M ▲ |
 Ultomiris | $0 ▲ | $0 ▲ | $240.00M ▲ | $710.00M ▲ |
 Vaxzevria | $0 ▲ | $0 ▲ | $0 ▲ | $30.00M ▲ |
 Zoladex | $200.00M ▲ | $240.00M ▲ | $0 ▼ | $230.00M ▲ |
 Arimidex | $60.00M ▲ | $30.00M ▼ | $30.00M ▲ | $0 ▼ |
 Casodex | $60.00M ▲ | $40.00M ▼ | $20.00M ▼ | $0 ▼ |
 Iressa | $120.00M ▲ | $50.00M ▼ | $0 ▼ | $0 ▲ |
 Atacand | $60.00M ▲ | $20.00M ▼ | $0 ▼ | $0 ▲ |
 Byetta | $30.00M ▲ | $20.00M ▼ | $0 ▼ | $0 ▲ |
 Cardiovascular Renal And Metabolism Products | $1.66Bn ▲ | $2.02Bn ▲ | $0 ▼ | $0 ▲ |
 Covid19 | $0 ▲ | $860.00M ▲ | $0 ▼ | $0 ▲ |
 Covid19 Vaccine Astrazeneca C19vaz | $0 ▲ | $860.00M ▲ | $0 ▼ | $0 ▲ |
 Losec Prilosec | $70.00M ▲ | $50.00M ▼ | $0 ▼ | $0 ▲ |
 Oncology Products | $2.17Bn ▲ | $3.29Bn ▲ | $0 ▼ | $0 ▲ |
 Other Cardiovascular Renal And Metabolism Products | $70.00M ▲ | $50.00M ▼ | $0 ▼ | $0 ▲ |
 Other Diabetes | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
 Other Oncology Products | $30.00M ▲ | $10.00M ▼ | $0 ▼ | $0 ▲ |
 Other Products | $640.00M ▲ | $450.00M ▼ | $0 ▼ | $0 ▲ |
 Other Products Others | $30.00M ▲ | $30.00M ▲ | $0 ▼ | $0 ▲ |
 Other Respiratory Products | $70.00M ▲ | $130.00M ▲ | $0 ▼ | $0 ▲ |
 Respiratory Products | $1.25Bn ▲ | $1.42Bn ▲ | $0 ▼ | $0 ▲ |
 Seroquel Xr Ir | $30.00M ▲ | $20.00M ▼ | $0 ▼ | $0 ▲ |
 Duaklir | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Movantik Moventig | $50.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Symlin | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Tudorza Eklira | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Pascal Claude Roland Soriot
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Drug Manufacturers - General
Sector Healthcare
Went public May 12, 1993
Method of going public Dual Listing
Full time employees 94,300
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-07-27 | Forward | 2:1 |
| 1998-04-08 | Forward | 3:1 |
ETFs Holding This Stock
Summary
Total 193
Showing Top 3 of 193
Ratings Snapshot
Rating : B+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 4
Debt To Equity 1
Price To Earnings 2
Price To Book 2
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 1
Showing Top 1 of 1
Price Target
Target High $108
Target Low $97
Target Median $103
Target Consensus $102.67
Institutional Ownership
PRICE T ROWE ASSOCIATES INC /MD/
Shares:49.12M
Value:$4.73B
PRIMECAP MANAGEMENT CO/CA/
Shares:39.86M
Value:$3.84B
BANK OF AMERICA CORP /DE/
Shares:32.63M
Value:$3.14B
Summary
% Of Shares Owned 11.01%
Total Number Of Holders 1,646
Showing Top 3 of 1,646